AdaptHealth (NASDAQ:AHCO) Shares Gap Up on Insider Buying Activity

AdaptHealth Corp. (NASDAQ:AHCO) gapped up prior to trading on Friday after an insider bought additional shares in the company. The stock had previously closed at $9.75, but opened at $10.25. AdaptHealth shares last traded at $10.35, with a volume of 232,281 shares changing hands.

Specifically, major shareholder Richard M. Cashin, Jr. acquired 689,336 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were acquired at an average cost of $9.73 per share, for a total transaction of $6,707,239.28. Following the transaction, the insider directly owned 15,864,871 shares of the company’s stock, valued at approximately $154,365,194.83. This represents a 4.54% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Richard M. Cashin, Jr. purchased 536,827 shares of the stock in a transaction dated Wednesday, March 11th. The stock was acquired at an average price of $9.73 per share, for a total transaction of $5,223,326.71. Following the completion of the transaction, the insider directly owned 15,175,535 shares of the company’s stock, valued at approximately $147,657,955.55. The trade was a 3.67% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In related news, major shareholder Richard M. Cashin, Jr. acquired 820,528 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $9.73 per share, for a total transaction of $7,983,737.44. Following the transaction, the insider directly owned 14,638,708 shares of the company’s stock, valued at approximately $142,434,628.84. This trade represents a 5.94% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on AHCO shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $13.00 target price on shares of AdaptHealth in a report on Wednesday, February 25th. Leerink Partners cut their price target on AdaptHealth from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Wall Street Zen downgraded AdaptHealth from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Zacks Research raised AdaptHealth from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings cut AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a research report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, AdaptHealth presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Key AdaptHealth News

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Major shareholder Richard M. Cashin Jr. executed multiple buys over March 10–12 totaling roughly 2.05 million shares (~$19.9M) at about $9.73/share, lifting his stake to ~15.86M shares — a strong insider vote of confidence that likely supported the rally. Investing.com article
• Positive Sentiment: Other filings and coverage show the same insider purchases (disclosed to the SEC) and note a multi-day, material increase in Cashin’s position — reinforcing the market interpretation of the buy as strategic accumulation rather than one-off trading. InsiderTrades article
• Positive Sentiment: Institutional activity shows selective buying (e.g., Goldman Sachs, UBS, new position from Woodline), which can add buying pressure and liquidity support. MarketBeat institutional note
• Neutral Sentiment: Analyst coverage is mixed — several “outperform”/buy ratings and raises to price targets offset by some downgrades and cuts; consensus is a moderate-buy with an average target ~ $13.25, so analyst views provide both support and caution. MarketBeat analyst summary
• Neutral Sentiment: Valuation write-ups are assessing the stock after recent weakness — useful for longer-term context but not an immediate catalyst. Yahoo Finance article
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent (shows 0 shares/NaN increases), so don’t read too much into those numbers until corrected filings are available.
• Negative Sentiment: Recent quarterly results (Feb. 24) included a large EPS miss (reported -$0.76 vs. consensus $0.34) and slight revenue decline year-over-year — fundamental weakness that has pressured valuation and explains earlier share-price weakness. SEC / MarketBeat filing

AdaptHealth Price Performance

The company’s 50 day simple moving average is $10.10 and its 200 day simple moving average is $9.68. The company has a current ratio of 1.02, a quick ratio of 0.81 and a debt-to-equity ratio of 1.15. The stock has a market capitalization of $1.44 billion, a PE ratio of -19.27, a PEG ratio of 1.12 and a beta of 1.76.

AdaptHealth (NASDAQ:AHCO) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of $0.34 by ($1.10). The business had revenue of $846.29 million for the quarter, compared to analysts’ expectations of $832.51 million. AdaptHealth had a positive return on equity of 3.42% and a negative net margin of 2.18%.The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.34 EPS. On average, equities analysts anticipate that AdaptHealth Corp. will post 0.88 earnings per share for the current year.

Institutional Trading of AdaptHealth

A number of hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of AdaptHealth by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock valued at $656,000 after acquiring an additional 2,564 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of AdaptHealth by 32.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock worth $6,192,000 after acquiring an additional 139,828 shares during the period. Woodline Partners LP acquired a new stake in shares of AdaptHealth in the first quarter worth approximately $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in AdaptHealth by 18.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock valued at $2,534,000 after purchasing an additional 35,879 shares during the period. Finally, Envestnet Asset Management Inc. grew its holdings in AdaptHealth by 115.3% in the second quarter. Envestnet Asset Management Inc. now owns 152,679 shares of the company’s stock valued at $1,440,000 after purchasing an additional 81,760 shares during the period. 82.67% of the stock is owned by institutional investors and hedge funds.

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.